Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Researchers identify defective signaling pathway that contributes to the severity of cystic fibrosis

In a study that could lead to new therapeutic targets for patients with the cystic fibrosis, a research team from the University of California, San Diego School of Medicine has identified a defective signaling pathway that contributes to disease severity.

15 Feb 2010

Hypnosis has potential therapeutic value in children with respiratory disorders

Hypnosis has potential therapeutic value in children with respiratory disorders for alleviating symptoms such as habit cough or unexplained sensations of difficulty breathing and for lessening a child's discomfort during medical procedures.

15 Feb 2010

Critical phases of brain development may be mistimed in autistic patients, says study

Research into Fragile X Syndrome - a genetic condition that is the leading known cause of autism - has discovered that critical phases in the brain's development may be mistimed in people with the condition.

11 Feb 2010

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.

11 Feb 2010

Mutations that enable Pseudomonas to thrive in cystic fibrosis lung secretions may also guard them against antibiotics

People with cystic fibrosis, an inherited disease that clogs airways with thick mucous, frequently have lung infections that defy treatment. While the life expectancy for children with cystic fibrosis has increased over the past few decades, many lives are still shortened in young adulthood by the ravages of lung infections.

10 Feb 2010

Kamada commences enrollment in European inhaled AAT clinical trial for alpha-1 antitrypsin deficiency

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.

9 Feb 2010

CREON effective in improving CFA and CNA in pediatric patients with EPI due to CF

Solvay Pharmaceuticals, Inc. announced that Phase IIIb data published in the January issue of Clinical Therapeutics confirm that CREON® (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in children aged 7-11 years who have exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food.

5 Feb 2010

Aradigm's first U.S. sale of SUMAVEL DosePro needle-free delivery system triggers $4M milestone payment

Aradigm Corporation announced today that it received the $4 million milestone payment from Zogenix, Inc. (“Zogenix”) based upon the first commercial sale in the U.S. of SUMAVEL* DosePro* (sumatriptan injection) needle-free delivery system. The Company will receive quarterly royalty payments on all SUMAVEL DosePro sales. In 2006, the Company sold all assets related to the Intraject* needle-free injector technology (now rebranded as DosePro) to Zogenix in exchange for milestone and royalty payments.

5 Feb 2010

Phase 2a clinical trial results of VX-809 in patients with CF announced

Vertex Pharmaceuticals Incorporated today announced results from a preliminary analysis of data from a 28-day Phase 2a clinical trial of VX-809 in patients with cystic fibrosis (CF) who are homozygous for the F508del mutation.

4 Feb 2010

NanoBio awarded sixth U.S. patent covering its novel nanoemulsion technology

NanoBio Corporation announced today that a sixth U.S. patent covering its novel nanoemulsion technology has been awarded. The patent encompasses composition of matter claims for the company’s lead anti-infective and vaccine product candidates.

3 Feb 2010

MPM Capital leads Alnara Pharmaceuticals' $35M Series B venture capital financing

Alnara Pharmaceuticals, Inc., a pharmaceutical company developing non-systemic, orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that it has secured $35 million in Series B venture capital financing. The round was led by new investor MPM Capital, joined by current investors Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners. In conjunction with the MPM investment, managing director Ashley Dombkowski, Ph.D., will join Alnara’s board of directors.

28 Jan 2010

NYU professor conducts genetic screening at academic campuses in Boston

Dr. Harry Ostrer, professor of pediatrics, pathology and medicine at NYU Langone Medical Center will be conducting genetic screening at four college campuses in Boston on February 1st and 2nd. Individuals interested in being screened should sign- up online at www.med.nyu.edu/genetics.

28 Jan 2010

UCSB research: Rapamycin drug, a potential treatment for ADPKD

Research performed at UC Santa Barbara points to the drug rapamycin as a potential treatment for kidney disease. The study builds on past research and shows that studies performed on mice are more likely to translate to humans than previously thought.

27 Jan 2010

Simple, five minute saliva test to determine baby's risk for more than 100 life-threatening genetic diseases

Genetic diseases like those seen in the new Harrison Ford movie "Extraordinary Measures" can now be prevented with a simple saliva test which is free with insurance for more than 100 million Americans.

22 Jan 2010

Combination of saliva test with ultra high-tech biopsy process may help prevent genetic disorders

Florida's largest fertility clinic announced it is the first in the state to offer promising new tests against birth defects: a coupling of technologies that will allow couples to avoid passing along more than 100 genetic diseases to their newborn.

22 Jan 2010

TUM biophysicists map changes in energy landscape of zipper-like protein molecule

Biophysicists at TUM, the Technische Universitaet Muenchen, have published the results of single-molecule experiments that bring a higher-resolution tool to the study of protein folding. How proteins arrive at the three-dimensional shapes that determine their essential functions - or cause grave diseases when folding goes wrong - is considered one of the most important and least understood questions in the biological and medical sciences.

20 Jan 2010

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

PTC Therapeutics, Inc. (PTC) today announced the initiation of an additional clinical trial of ataluren (PTC124®) in boys and young men with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who have permanently lost the ability to walk independently.

20 Jan 2010

One of Cystic Fibrosis Foundation's active volunteers to carry Olympic Torch in Calgary

One of the Cystic Fibrosis Foundation's most active volunteers will carry the Olympic Torch today in Calgary as it makes its way to Vancouver for the Opening Ceremony of the 2010 Olympic Winter Games.

19 Jan 2010

Flexpoint to develop infant bed cover using patented Bend Sensor® design

Flexpoint Sensor Systems, Inc. announced that they are working on the development of an infant bed cover using their patented Bend Sensor® design. The mattress will be used to monitor infants in the prevention of sudden infant death syndrome (“SIDS”).

18 Jan 2010

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

KaloBios Pharmaceuticals, Inc. today announced an agreement with Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, for the development and commercialization of KB001, an investigational new biologic for the treatment or prevention of Pseudomonas aeruginosa (Pa) infections. Sanofi Pasteur will be responsible for the development and commercialization of KB001 and initially focus on hospital indications, including the prevention of Pa pneumonias in mechanically ventilated patients.

11 Jan 2010

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Researchers identify defective signaling pathway that contributes to the severity of cystic fibrosis

Hypnosis has potential therapeutic value in children with respiratory disorders

Critical phases of brain development may be mistimed in autistic patients, says study

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

Mutations that enable Pseudomonas to thrive in cystic fibrosis lung secretions may also guard them against antibiotics

Kamada commences enrollment in European inhaled AAT clinical trial for alpha-1 antitrypsin deficiency

CREON effective in improving CFA and CNA in pediatric patients with EPI due to CF

Aradigm's first U.S. sale of SUMAVEL DosePro needle-free delivery system triggers $4M milestone payment

Phase 2a clinical trial results of VX-809 in patients with CF announced

NanoBio awarded sixth U.S. patent covering its novel nanoemulsion technology

MPM Capital leads Alnara Pharmaceuticals' $35M Series B venture capital financing

NYU professor conducts genetic screening at academic campuses in Boston

UCSB research: Rapamycin drug, a potential treatment for ADPKD

Simple, five minute saliva test to determine baby's risk for more than 100 life-threatening genetic diseases

Combination of saliva test with ultra high-tech biopsy process may help prevent genetic disorders

TUM biophysicists map changes in energy landscape of zipper-like protein molecule

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

One of Cystic Fibrosis Foundation's active volunteers to carry Olympic Torch in Calgary

Flexpoint to develop infant bed cover using patented Bend Sensor® design

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in